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ABSTRACT
Background Simple and inexpensive non-invasive
ﬁbrosis tests are highly needed but have been poorly
studied in sub-Saharan Africa.
Methods Using liver histology as a gold standard, we
developed a novel index using routine laboratory tests to
predict signiﬁcant ﬁbrosis in patients with chronic HBV
infection in The Gambia, West Africa. We prospectively
assessed the diagnostic accuracy of the novel index,
Fibroscan, aspartate transaminase-to-platelet ratio index
(APRI), and Fib-4 in Gambian patients with CHB
(training set) and also in French and Senegalese CHB
cohorts (validation sets).
Results Of 135 consecutive treatment-naïve patients
with CHB who had liver biopsy, 39% had signiﬁcant
ﬁbrosis (Metavir ﬁbrosis stage ≥F2) and 15% had
cirrhosis (F4). In multivariable analysis, gamma-glutamyl
transpeptidase (GGT) and platelet count were
independent predictors of signiﬁcant ﬁbrosis.
Consequently, GGT-to-platelet ratio (GPR) was
developed. In The Gambia, the area under the receiver
operating characteristic curve (AUROC) of the GPR was
signiﬁcantly higher than that of APRI and Fib-4 to
predict ≥F2, ≥F3 and F4. In Senegal, the AUROC of
GPR was signiﬁcantly better than Fib-4 and APRI for
≥F2 (0.73, 95% CI 0.59 to 0.86) and better than Fib-4
and Fibroscan for ≥F3 (0.93, 0.87 to 0.99). In France,
the AUROC of GPR to diagnose ≥F2 (0.72, 95% CI
0.59 to 0.85) and F4 (0.87, 0.76 to 0.98) was
equivalent to that of APRI and Fib-4.
Conclusions The GPR is a more accurate routine
laboratory marker than APRI and Fib-4 to stage liver
ﬁbrosis in patients with CHB in West Africa. The GPR
represents a simple and inexpensive alternative to liver
biopsy and Fibroscan in sub-Saharan Africa.
INTRODUCTION
HBV infection is highly endemic in sub-Saharan
Africa (SSA)1 and is the main cause of hepatocellu-
lar carcinoma (HCC), one of the most frequent
cancers in Africa.2 3 Immunisation is not sufﬁcient
to control the HBV epidemic in SSA.4 To reduce
the disease burden of HBV infection in SSA, it may
be critical to identify HBV-infected subjects with
signiﬁcant liver disease and treat them with anti-
viral therapy.
Signiﬁcance of this study
What is already known on this subject?
▸ HBV infection is responsible for a signiﬁcant
burden of liver disease in sub-Saharan Africa
(SSA).
▸ The lack of non-invasive and inexpensive
ﬁbrosis markers for the assessment of chronic
HBV infection is one of the main barriers for
care and treatment of people chronically
infected with HBV in Africa.
▸ WHO recommends the use of aspartate
transaminase-to-platelet ratio index (APRI) as a
non-invasive test for cirrhosis in
resource-limited settings, however, the evidence
is limited in SSA where only two small studies
have assessed the diagnostic performance of
the non-invasive markers.
▸ A new simple and inexpensive marker of
ﬁbrosis in SSA is highly needed.
What are the new ﬁndings?
▸ For identifying signiﬁcant ﬁbrosis and cirrhosis
in West African HBV carriers, the new GPR
(gamma-glutamyl transpeptidase (GGT)/
platelets ratio) is a more accurate routine
laboratory test than APRI and Fib-4 tests.
▸ Transient elastography (Fibroscan) has excellent
diagnostic accuracy for predicting signiﬁcant
ﬁbrosis and cirrhosis in patients infected with
HBV in West African setting but the device
remains expensive.
▸ The GPR represents an accurate and
inexpensive alternative to liver biopsy and
Fibroscan for SSA countries.
How might it impact on clinical practice in
the foreseeable future?
▸ WHO is calling for better strategies to ﬁght
against the global burden of viral hepatitis in
particular in resource-poor settings. GGT and
platelets are inexpensive biomarkers, easy to
measure even in peripheral laboratories in SSA.
Thus, GPR will be easy to use in routine clinical
practice.
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Fibrosis staging is an essential step in the clinical assessment
of patients with chronic HBV (CHB) infection to identify those
who require treatment. Liver biopsy (LB) is an invasive and
expensive procedure that is very difﬁcult to perform in routine
practice in SSA. Thus, non-invasive methods to evaluate liver
ﬁbrosis are particularly needed in SSA.
Transient elastography (Fibroscan) is a point-of-care proced-
ure that has been validated in patients with CHB infection in
Western and Asian countries.5–10 Simple biochemical markers
such as the aspartate transaminase (AST)-to-platelet ratio index
(APRI)11 and the ﬁbrosis-4 (Fib-4)12 scores have the advantage
of comprising only two or three inexpensive laboratory tests. In
March 2015, WHO published its ﬁrst guidelines on the manage-
ment of CHB infection. They recommend the use of APRI as a
non-invasive tool to detect liver cirrhosis and signiﬁcant ﬁbrosis
in resource-limited settings.13 However, these guidelines also
underline a need for additional evidence from SSA. Indeed,
only two small studies to date assessed the diagnostic perform-
ance of non-invasive markers of ﬁbrosis in SSA.14 15
Within the framework of the PROLIFICA programme
(Prevention of Liver Fibrosis and Cancer in Africa, funded by
the European Commission FP7, P34114)16 we identiﬁed a new
simple laboratory index, the gamma-glutamyl transpeptidase
(GGT)-to-platelet ratio (GPR), in a cohort of CHB carriers in
The Gambia, West Africa and then assessed its diagnostic accur-
acy in two external validation sets from France17 and Senegal.15
We compared the diagnostic performance of GPR with that of
Fibroscan, APRI and Fib-4 tests, using liver histology as a gold
standard.
METHODS
Patients
From November 2011 to November 2013, all consecutive
patients with positive hepatitis B surface antigen test
(Determine, Alere, USA)18 enrolled in the PROLIFICA pro-
gramme in The Gambia underwent a standardised clinical exam-
ination including Fibroscan, abdominal ultrasound and blood
tests: haematology (Medonic SE-12613, Boule Medical AB,
Sweden); biochemistry (VITROS 350 analyser, Ortho, USA);
hepatitis B e antigen (ETI-EBK Plus, Diasorin, Italy); antibody
against HCV (anti-HCV) (AxSYM, Abbott, USA); antibody
against hepatitis D virus (ETI-AB-DELTAK-2, Diasorin, Italy);
antibody against HIV (anti-HIV) (Genscreen ULTRA, Biorad,
USA); and HBV DNA using a quantitative in-house PCR (detec-
tion limit: 50 IU/mL). The data were prospectively collected
using a speciﬁc case report form. Patients with at least one of
the criteria below were invited for LB in the absence of contra-
indications: transaminases (AST or alanine transaminase (ALT))
≥40 IU/L, liver stiffness measurement (LSM) ≥6.5 kPa, family
history of cirrhosis or HCC in a ﬁrst-degree relative, or HBV
DNA ≥2000 IU/mL. Subjects with the following conditions
were excluded from the study: co-infection with HCV, hepatitis
D virus or HIV, prior or concurrent HBV antiviral therapy, focal
hepatic lesion including HCC, concomitant tuberculosis, acute
malaria, transaminases levels more than 10 times the upper limit
of normal (ULN),19 signiﬁcant alcohol consumption (>20 g/
day), acute heart failure and pregnancy.
Liver biopsy
Percutaneous LB was performed using ultrasound localisation
and the Menghini technique after written informed consent.
Liver samples were formalin-ﬁxed and parafﬁn-embedded for
histological analysis. Liver histology was interpreted by two liver
pathologists in The Gambia and England. Liver samples with
less than three portal tracts were considered as poor quality and
therefore excluded from the analysis. Both pathologists were
blinded to the clinical information including the results of non-
invasive tests. In case of discrepancies, slides were reviewed by a
third highly experienced hepatopathologist (UK) who was
blinded to the clinical information and the diagnosis of the
other pathologists. The degree of liver activity and ﬁbrosis were
scored according to the Metavir system.20
Transient elastography (Fibroscan)
All LSMs were performed fasting21 on the same day of LB using
a Fibroscan device (FS402, Echosens, France) by experienced
operators according to the manufacturer’s protocol.22 The value
of LSM was expressed in kilopascal (kPa) as the median of 10
successful acquisitions. Unreliable measurement was deﬁned as
IQR/LSM of >0.30 when LSM is ≥7.1 kPa.23
APRI and Fib-4 calculation
APRI and Fib-4 were calculated as (AST (IU/L)/its ULN)/platelet
count (109/L)×10011 and as (age (years)×AST (IU/L))/(platelets
(109/L)×(ALT (IU/L))1/2),12 respectively. These markers were
measured at enrolment, usually 1–2 weeks prior to the LB.
Validation sets
Two external validation data sets of treatment-naïve monoin-
fected CHB carriers with viral load ≥2000 IU/mL and without
excessive alcohol intake from France17 and Senegal15 were used
to assess the performance of the novel index and other non-
invasive markers. In the French cohort (n=138), only the
patients with available data on GGT and platelet counts and a
length of liver fragment >15 mm were included in the current
analysis (n=63). Fibroscan was not performed in this cohort. In
Senegal, only the patients with LSM ranging between 7 kPa and
13 kPa underwent LB following the scientiﬁc committee’s rec-
ommendation, and the original analysis was restricted to
patients with normal ALT (n=69).15 In the current analysis, we
also included patients who had elevated ALT, and thus we ana-
lysed 80 Senegalese patients.
Statistical analysis
The baseline characteristics of the three cohorts were compared
using χ2 test or Kruskal-Wallis test. In order to identify predic-
tors of signiﬁcant liver ﬁbrosis (≥F2), univariable logistic regres-
sion was computed for the following variables: age, sex, AST,
ALT, alkaline phosphatase, GGT, albumin, total bilirubin, plate-
let count and HBV DNA levels. All the continuous variables
were transformed in logarithmic scale. Multiple logistic regres-
sion models were then ﬁtted by including all the factors asso-
ciated with the signiﬁcant liver ﬁbrosis in the univariable
analyses (two-sided p value of <0.05), and the ﬁnal prediction
model was selected using the backward stepwise procedures. A
simpliﬁed formula was derived using the independent predictors
of the ﬁnal model.
The diagnostic accuracy of established ﬁbrosis markers
(Fibroscan, APRI and Fib-4) and the new index (GPR) was esti-
mated by using the receiver operating characteristic (ROC)
curve. Optimal cut-offs for LSM and GPR were selected to
maximise the sum of sensitivity and speciﬁcity. For APRI and
Fib-4, predeﬁned cut-offs were used (0.5 and 1.5 for APRI to
distinguish F0–1 and F2–4, 1.0 and 2.0 for APRI to distinguish
F0–3 and F4,11 and 1.45 and 3.25 for Fib-4 to distinguish F0–2
and F3–412). The sensitivity, speciﬁcity, positive and negative
predictive values and the area under the ROC curve (AUROC)
of each non-invasive test for signiﬁcant ﬁbrosis (F≥2), extensive
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ﬁbrosis (F≥3) and cirrhosis (F4) were obtained by comparing
patients of F2–4 with F0–1, F3–4 with F0–2, and F4 with F0–
3, respectively. AUROC was compared between non-invasive
tests for each ﬁbrosis stage. In order to assess the associations of
liver ﬁbrosis stages, activity grade and presence of steatosis with
a score of each non-invasive marker, a linear regression was
modelled. The effects of these factors were mutually adjusted in
a multivariable analysis. Finally, the GPR was applied to the two
validation data sets and AUROC was obtained. All the analyses
were performed using STATAV.13.0 (Stata Corporation, College
Station, Texas). This study was reported in accordance with the
Standards for Reporting of Diagnostic Accuracy (STARD).24
RESULTS
Training set in The Gambia
Study population
Between November 2011 and November 2013, 1042 subjects
tested positive for hepatitis B surface antigen were prospectively
enrolled in the Prevention of Liver Fibrosis and Cancer in
Africa (PROLIFICA) programme in The Gambia. Figure 1 sum-
marises the ﬂow diagram of the study population. After exclu-
sion of patients with HCC (n=113) or other diagnoses (n=9),
225 (24.5%) met the study criteria for LB and were invited.
Sixty-eight (30.2%) refused the procedure. The clinical and bio-
logical characteristics of subjects who refused the procedure
were not statistically different from those who accepted the pro-
cedure (data not shown). Eleven procedures were cancelled on
the day of LB (ﬁgure 1). Thus, 146 LBs were performed. Of
them, 11 were excluded from the analysis (reasons are indicated
in ﬁgure 1). Thus, 135 patients were included in the ﬁnal ana-
lysis. All patients had reliable LSM values using the criteria pro-
posed by Boursier et al.23 Indication for LB was as follows:
elevated transaminases alone (9, 6.7%), elevated LSM alone
(39, 28.8%), elevated viral load alone (7, 5.1%), family history
of cirrhosis or HCC alone (5, 3.7%), and combination of two
or more of these (75, 55.5%). Table 1 summarises the main
characteristics of the study patients.
Histopathology
No complication was observed after LB. Fifty-three (39%)
patients had ﬁbrosis ≥F2 and 20 (15%) had cirrhosis. A third of
patients (37; 27%) had liver activity A2/A3 and the vast major-
ity of the patients had no liver steatosis (table 1). Both patholo-
gists were initially in agreement for 94 (69.6%) specimens. For
the 41 specimens showing discrepancies, a ﬁnal diagnosis was
reached by a third histopathologist (ﬁgure 1).
The GPR predicts signiﬁcant liver ﬁbrosis
The presence of signiﬁcant liver ﬁbrosis (≥F2) was associated
with male sex, AST, ALT, GGT, albumin, platelet count and
HBV DNA levels in univariable analyses (table 2). Subsequent
multivariable analysis using backward stepwise procedures iden-
tiﬁed GGT and platelet count as independent predictors of sig-
niﬁcant ﬁbrosis.
Box plots of GGT and platelet count in relation to the
Metavir ﬁbrosis stage are presented in ﬁgure 2A, B. While GGT
values had a positive correlation with Metavir score
(Spearman’s correlation coefﬁcient r=0.48, p<0.0001), platelet
count was negatively correlated (r=−0.33, p=0.0001). In order
to improve the prediction of signiﬁcant ﬁbrosis using these vari-
ables, a novel index called the GPR was derived as GGT/ULN
of GGT/platelet count (109/L)×100.
There was a statistically signiﬁcant positive correlation
between GPR and Metavir ﬁbrosis stage (ﬁgure 2C), with a
higher correlation coefﬁcient than GGT or platelet count alone
(r=0.53, P<0.0001). AUROC for predicting signiﬁcant ﬁbrosis
was higher with GPR (0.80, 95% CI 0.72 to 0.88) than using
GGT alone (0.77, 95% CI 0.68 to 0.85, p=0.07) or platelet
count alone (0.70, 95% CI 0.61 to 0.79, p=0.02).
Comparisons of AUROC between GPR and other established
non-invasive markers
In The Gambian cohort, the GPR and established non-invasive
markers (LSM, APRI and Fib-4) increased with increasing liver
ﬁbrosis stage (ﬁgure 2D–F). For the prediction of signiﬁcant
ﬁbrosis (≥F2), AUROC of GPR (0.80, 95% CI 0.72 to 0.88)
Figure 1 Flow diagram of the study population and reasons for exclusion, from November 2011 to November 2013, The Gambia. CHB, chronic
HBV; HCC, hepatocellular carcinoma; HDV, hepatitis D virus; LB, liver biopsy; TB, tuberculosis.
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was signiﬁcantly higher than that of APRI (0.66, 95% CI 0.57
to 0.76, p<0.001) and Fib-4 (0.66, 95% CI 0.56 to 0.76,
p=0.003), but not higher than LSM (0.85, 95% CI 0.78 to
0.91, p=0.2) (table 3). For predicting signiﬁcant ﬁbrosis the
optimal cut-off value of GPR was 0.32.
For predicting cirrhosis, AUROC of GPR (0.83, 95% CI 0.72
to 0.94) was signiﬁcantly better than that of APRI (0.70, 95% CI
0.55 to 0.86, p=0.03) and Fib-4 (0.73, 95% CI 0.58 to 0.87,
p=0.03) although the AUROC of GPR was signiﬁcantly inferior
to LSM (0.98, 95% CI 0.97 to 1.00, p=0.003) (table 3). The
optimal cut-off value of GPR for cirrhosis was 0.56.
The AUROC of each marker did not change substantially
when the analysis was restricted to the subjects with liver speci-
men ≥12 mm (data not shown). Among ﬁbrosis stage, activity
grade and steatosis, ﬁbrosis was the only parameter signiﬁcantly
associated with GPR (p<0.001), LSM (p<0.001), APRI
(p=0.008) and Fib-4 scores (p=0.006) in multiple linear
regression.
Validation set in Senegal
In the Senegalese cohort (n=80), 18 (23%) were F0, 36
(45.0%) were F1, 17 (21%) were F2 and 9 (11%) were F3
based on the liver histology results (table 1). None had cirrhosis
since the study protocol did not allow LB in patients with sus-
pected cirrhosis.
For predicting signiﬁcant ﬁbrosis, the AUROC of GPR (0.73,
95% CI 0.59 to 0.86) was higher than that of Fib-4 (0.57, 95%
CI 0.42 to 0.71, p=0.04) and APRI (0.62, 95% CI 0.48 to
0.76, p=0.05). For predicting extensive ﬁbrosis, the AUROC of
GPR (0.93, 95% CI 0.87 to 0.99) was signiﬁcantly better than
that of Fib-4 (0.71, 95% CI 0.53 to 0.89, p=0.02) and
Fibroscan (0.71, 95% CI 0.53 to 0.89, p=0.04). There was no
signiﬁcant difference between GPR and APRI (0.89, 95% CI
0.80 to 0.98, p=0.3). Using the optimal cut-off value deter-
mined in the Gambian training set (0.32), the sensitivity and
speciﬁcity of GPR to predict severe ﬁbrosis was 89% and 80%,
respectively (table 3).
Validation set in France
In the French cohort (n=63), ﬁbrosis stage according to histo-
pathology was as follows: 6 (10%) in F0, 27 (43%) in F1, 15
(24%) in F2, 11 (17%) in F3 and 4 (6%) in F4 (table 1).
The performance of GPR was as good as APRI and Fib-4:
AUROC at 0.72 (95% CI 0.59 to 0.85) to predict signiﬁcant
ﬁbrosis, 0.76 (95% CI 0.62 to 0.90) for extensive ﬁbrosis and
0.87 (95% CI 0.76 to 0.98) for cirrhosis (table 3). Applying the
optimal cut-off (0.56) determined in the training data set, the
sensitivity and speciﬁcity of GPR to predict cirrhosis were 100%
and 68%, respectively (table 3).
DISCUSSION
Assessing the severity of CHB infection is one of the main bar-
riers for offering care and treatment to CHB carriers in SSA. In
Table 1 Baseline characteristics of the study population in training set (The Gambia) and in validation sets (France and Senegal)
Variables The Gambia (n=135) France (n=63) Senegal (n=80) p Value
Male sex, n 105 (78%) 41 (65%) 67 (84%) 0.03
Median age (years) (IQR) 34 (29–39) 38 (29–49) 28 (24–31) <0.001
Median BMI (kg/m2) (IQR) 21.6 (19.9–24.8) Not reported 20.9 (18.9–24.0) 0.1
Median fasting LSM value (kPa) 7.5 (6.5–9.2) Not reported 8.8 (7.8–10.2) <0.001
Median IQR of LSM (kPa) 1.3 (0.9–1.8) Not reported 1.4 (1.1–2.6) 0.006
Median ALT (IU/L) (IQR) 30 (23–49) 61 (39–125) 39 (30–53) <0.001
Median AST (IU/L) (IQR) 36 (29–48) 36 (28–66) 41 (31–53) 0.4
Median GGT (IU/L) (IQR) 36 (24–59) 32 (18–52) 26 (22–42) 0.002
Median total bilirubin (IU/L) (IQR) 11 (9–15) 11 (8–14) 12 (9–14) 0.4
Median platelet counts (109/L) (IQR) 177 (136–226) 171 (143–210) 179 (156–210) 0.5
Negative HBeAg, n 129 (96%) 28 (60%) 66 (83%) <0.001
Median HBV DNA level (log10 IU/mL) (IQR) 2.6 (1.9–4.5) 5.7 (4.4–7.1) 3.9 (3.5–5.2) <0.001
Median APRI (IQR) 0.52 (0.37–0.82) 0.56 (0.31–1.01) 0.55 (0.41–0.80) 0.7
Median Fib-4 (IQR) 1.30 (0.86–1.84) 1.09 (0.75–1.69) 0.96 (0.74–1.32) <0.001
Median size of liver biopsy (mm) (IQR) 11 (8–12) 20 (17–25) 28 (22–32) <0.001
Metavir fibrosis stage (F0/F1/F2/F3/F4) 28 (21%)/54 (40%)/10 (7%)/
23 (17%)/20 (15%)
6 (10%)/27 (43%)/15 (24%)/
11 (17%)/4 (6%)
18 (23%)/36 (45%)/17 (21%)/
9 (11%)/0 (0%)
<0.001
Metavir activity grade (A0/A1/A2/A3) 30 (22%)/68 (50%)/23 (17%)/14 (10%) Not reported 42 (53%)/29 (37%)/8 (10%)/0 (0%) <0.001
Steatosis (none/mild/moderate/severe) 125 (93%)/6 (4%)/4 (3%)/0 (0%) 30 (64%)/15 (32%)/2 (4%)/0 (0%) 73 (91%)/7 (9%)/0 (0%)/0 (0%) <0.001
ALT, alanine transaminase; APRI, (AST)-to-platelet ratio index; AST, aspartate transaminase; BMI, body mass index; HBeAg, hepatitis B e antigen; GGT, gamma-glutamyl transpeptidase;
LSM, liver stiffness measurement.
Table 2 Crude analysis for factors associated with the presence of
significant fibrosis (F2–4) in the training set, in The Gambia
Factors*
No or mild
fibrosis
n=82
Significant
fibrosis or more
n=53
Crude p
value†
Age (years) 36±10 35±11 0.7
Male sex, n (%) 58 (71) 47 (89) 0.02
AST (IU/L) 39±22 62±61 0.01
ALT (IU/L) 37±25 64±79 0.007
ALP (IU/L) 97±44 112±69 0.1
GGT (IU//L) 35±21 72±55 <0.001
Albumin (g/L) 43±4 41±11 0.003
Total bilirubin (IU/L) 12±5 17±21 0.1
Platelets (109/L) 201±67 185±183 0.007
HBV DNA (log10IU/mL) 6.9±7.8 8.5±9.3 0.01
*Continuous variables are presented as mean±SD.
† p Values were obtained using logarithmic transformed values except for sex.
ALT, alanine transaminase; ALP, alkaline phosphatase; AST, aspartate transaminase;
GGT, gamma-glutamyl transpeptidase.
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most resource-limited settings LB is impractical and Fibroscan is
rarely available.
Within the framework of the PROLIFICA programme in The
Gambia,16 we developed a new simple and inexpensive bio-
marker index, the GPR, to identify HBV-infected subjects with
signiﬁcant ﬁbrosis or cirrhosis in SSA. The AUROC of GPR to
predict ﬁbrosis and cirrhosis was generally high throughout the
Gambian cohort and two independent validation data sets
(from Senegal and France).
As previously reported in patients with chronic hepatitis
C25 26 and B6 27 from Western countries, Fibroscan performed
better than biochemical markers in the Gambian cohort with
excellent diagnostic accuracy for predicting signiﬁcant ﬁbrosis
and cirrhosis. In our study in The Gambia, LSMs were per-
formed fasting21 on the same day of the LB in contrast to other
studies which performed Fibroscan within 1 month, 6
months6 15 or even 12 months of the LB.14 Our best Fibroscan
cut-offs for signiﬁcant ﬁbrosis (7.9 kPa) and cirrhosis (9.5 kPa)
were close to those proposed in Western studies.6 28 Among
those included in the current analysis in The Gambia, none had
unreliable LSM. Indeed, in our study population obesity (body
mass index (BMI) ≥30 kg/m2), which is often associated with
unreliable measurement, was rarely observed (4.4%, 6/135). In
addition, because LSM was one of the criteria for the LB indica-
tion, patients with invalid measurement who did not meet other
criteria for biopsy were excluded.
Figure 2 Box plots of gamma-glutamyl transpeptidase (GGT) (A), platelet count (B), GGT to platelet ratio (GPR) (C), liver stiffness measurement
(LSM) (D), aspartate transaminase-to-platelet ratio index (APRI) (E), and Fib-4 (F) according to the Metavir ﬁbrosis stage in the Gambian cohort.
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Table 3 Diagnostic performances of GPR, Fibroscan, APRI and Fib-4 in the training set (The Gambia) and in validation sets (France and Senegal)*
The Gambia (n=135) France (n=63)† Senegal (n=80)‡
F0–1 vs F2–4 F0–2 vs F3–4 F0–3 vs F4 F0–1 vs F2–4 F0–2 vs F3–4 F0–3 vs F4 F0–1 vs F2–4 F0–2 vs F3–4
GPR
AUROC (95% CI) 0.80 (0.72 to 0.88) 0.81 (0.72 to 0.89) 0.83 (0.72 to 0.94) 0.72 (0.59 to 0.85) 0.76 (0.62 to 0.90) 0.87 (0.76 to 0.98) 0.73 (0.59 to 0.86) 0.93 (0.87 to 0.99)
Cut-off values§ 0.32 0.32 0.56 0.32 0.32 0.56 0.32 0.32
Sensitivity/specificity (%) 83/69 86/64 85/76 73/49 80/44 100/68 50/83 89/80
Correctly classified (%) 74 71 77 60 52 70 73 81
PPV/NPV (%) 63/86 53/91 39/97 56/67 31/88 17/100 59/78 36/98
Positive/negative LR 2.7/0.3 2.4/0.2 3.5/0.2 1.4/0.6 1.4/0.5 3.1/0.0 3.0/0.6 4.5/0.1
Fibroscan
AUROC (95% CI) 0.85 (0.78 to 0.91) 0.89 (0.82 to 0.95) 0.98 (0.97 to 1.00) 0.61 (0.48 to 0.74) 0.71 (0.53 to 0.89)
Cut-off values§ 7.9 8.2 9.5 7.9 8.2
Sensitivity/specificity (%) 81/81 93/82 100/89 81/30 89/41
Correctly classified (%) 81 85 90 46 46
PPV/NPV (%) 73/87 70/96 61/100 36/76 16/97
Positive/negative LR 4.2/0.2 5.0/0.1 8.9/0 1.1/0.6 1.5/0.3
APRI
AUROC (95% CI) 0.66 (0.57 to 0.76) 0.68 (0.58 to 0.78) 0.70 (0.55 to 0.86) 0.77 (0.65 to 0.89) 0.83 (0.72 to 0.93) 0.78 (0.57 to 0.98) 0.62 (0.48 to 0.76) 0.89 (0.80 to 0.98)
Cut-off values¶ 0.5 1.5 1.0 2.0 0.5 1.5 1.0 2.0 0.5 1.5
Sensitivity/specificity (%) 64/64 9/98 40/87 25/99 77/67 20/91 50/78 25/92 42/70 0/96
Correctly classified (%) 64 62 80 88 71 57 76 87 61 65
PPV/NPV (%) 54/73 71/62 35/89 75/87 68/76 67/56 13/96 17/95 41/72 0/67
Positive/negative LR 1.8/0.6 3.8/0.9 3.0/0.7 28/0.8 2.3/0.4 2.2/0.9 2.3/0.6 3.0/0.8 1.4/0.8 0.0/1.0
Indeterminate results (%) 42 13 40 14 31
Fib-4
AUROC (95% CI) 0.66 (0.56 to 0.76) 0.68 (0.57 to 0.78) 0.73 (0.58 to 0.87) 0.75 (0.62 to 0.88) 0.86 (0.77 to 0.95) 0.83 (0.69 to 0.98) 0.57 (0.42 to 0.71) 0.71 (0.53 to 0.89)
Cut-off values** 1.45 3.25 1.45 3.25 1.45 3.25
Sensitivity/specificity (%) 63/68 14/98 73/73 27/96 44/83 0/100
Correctly classified (%) 66 71 73 79 79 89
PPV/NPV (%) 48/79 75/70 46/90 67/81 25/92 NA/89
Positive/negative LR 1.9/0.5 6.3/0.9 2.7/0.4 6.4/0.8 2.6/0.7 1.0/NA
Indeterminate results (%) 36 29 20
Comparison of AUROC
GPR and Fibroscan p=0.2 p=0.02 p=0.003 N/A N/A N/A p=0.2 p=0.04
GPR and APRI p<0.001 p=0.002 p=0.03 p=0.4 p=0.2 p=0.3 p=0.05 P=0.3
GPR and Fib-4 p=0.003 p=0.01 p=0.03 p=0.6 p=0.1 p=0.6 p=0.04 P=0.02
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Despite its high diagnostic performance, the Fibroscan device
is still expensive (€34 000 for the portable machine) and
requires annual maintenance (€5000). Moreover, in Africa,
when available, the machine is often only accessible in the main
hospitals in the capital city or within the private sectors. In SSA
countries, where antiviral therapy using tenofovir has now
become available at generic cost and decentralisation of health-
care provision is recommended,29 there is an urgent need for
simple and inexpensive alternative methods for identifying
patients with CHB who need treatment. Consequently, the
recent WHO guidelines13 ranked APRI as a preferred non-
invasive test in resource-limited settings, rather than Fibroscan.
However, the accuracy of APRI observed in SSA (including our
study) is not acceptable. The AUROC of APRI to predict signiﬁ-
cant ﬁbrosis was 0.61 (95% CI 0.46 to 0.76) in Burkina Faso,14
0.62 (0.48 to 0.76) in Senegal and 0.66 (0.57 to 0.76) in The
Gambia, and for the prediction of cirrhosis it was 0.50 (0.32 to
0.68) in Burkina Faso and 0.70 (0.55 to 0.86) in The Gambia.
A similar low performance of Fib-4 has been constantly observed
in the Burkinabe study14 and ours in The Gambia and Senegal.
WHO guidelines13 also recommend a single cut-off of the APRI
score (2.0) to diagnose cirrhosis in resource-limited countries.
Whether this cut-off can be applied for SSA countries is highly
questionable because of the difference in natural history of CHB
infection; in Asia CHB carriers frequently experience active
hepatitis with elevated transaminase levels30 while in SSA the
vast majority are in inactive phase with normal transaminases.31
By applying the WHO cut-off of APRI, the sensitivity for the
diagnosis of cirrhosis in the Gambian cohort was only 25%. This
implies that 75% of patients with cirrhosis will be erroneously
categorised as patients without cirrhosis. In contrast the sensitiv-
ity of GPR to diagnose cirrhosis in The Gambia was 85% and
89% in Senegal to diagnose extensive ﬁbrosis. In patients with
CHB, GGT has been previously identiﬁed as an independent
variable of signiﬁcant ﬁbrosis32–34 and GPR was also suggested as
a potential biomarker of ﬁbrosis in a Turkish cohort.33
Our study in The Gambia also conﬁrmed the difﬁculty of per-
forming LB (a third of refusal) and sample preparations in SSA.
We reported 30.4% of interobserver discrepancy and we faced
several barriers obtaining good quality liver specimens mainly
due to difﬁculties in ﬁxing and cutting liver specimen in the
local warm environment where softening of parafﬁn renders the
cutting difﬁcult.
Our study in The Gambia has limitations. First, for ethical and
logistical reasons, the indication of LB depended on the results of
index tests under the investigation (AST, ALT and LSM), and we
could not invite all our HBV-infected participants for LB. As a
result, the patients included in the current analysis are not repre-
sentative of the general population with CHB infection in The
Gambia. This might have caused veriﬁcation bias resulting in
overestimated sensitivities and underestimated speciﬁcities of
these markers.35 Nevertheless, the GPR was free from this bias
because in absence of contraindications including platelets below
50,000/mm3, patients were invited for LB irrespective of their
GGT and platelet levels. Second, we acknowledge that our liver
specimens were relatively small and that only a small proportion
of our biopsies were over 15 mm, which is the current recom-
mendation.36 However, in a subgroup of Gambian patients with
a length of over 12 mm, AUROC of the non-invasive tests did
not improve. Third, we excluded conditions that may be asso-
ciated with elevated GGT (excessive alcohol consumption and
obesity) and low platelet count (alcohol, HIV and malaria).
Consequently, high diagnostic accuracy of the GPR may not be
generalisable in patients with such conditions.
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In summary, for the identiﬁcation of CHB carriers with signiﬁ-
cant ﬁbrosis or cirrhosis, non-invasive markers that depend on trans-
aminase levels (APRI and Fib-4) are not accurate enough to be used
in routine practice in SSA. Our study suggests that GPR may be a
simple, accurate and inexpensive alternative to LB and Fibroscan in
resource-constrained African settings. The GPR deserves to be
further validated in other African and non-African populations.
Acknowledgements The authors thank the MRC laboratories The Gambia unit, the
local ministry of health and social welfare for supporting the project, all the study
participants, the PROLIFICA team: in particular Ignatius Baldeh, Famara Bojang, Amie
Ceesay, Mavis Foster-Nyarko, Debbo Jallow, Abdulie Jatta, Adam Jeng, Sheriff Kolley,
Yamundow Jallow Samba, Alagie Sanneh, Bakary, Sanneh, Demba Sonko, Lamin Bojang,
Saydiba Tamba and Debbie Garside, the project manager of the PROLIFICA programme.
The authors also thank Professor Dominique Valla for his precious recommendations on
haemostatic precautions before liver biopsy in the local resource-constrained setting. The
authors also thank Dr Philippe Sultanik for his contributions to statistical analysis and Dr
Patrick Ingiliz for his constructive comments and suggestions.
Contributors All authors contributed to this study at different levels. All authors
read and approved the ﬁnal version. ML and YS designed the study and wrote the
paper. ML and RN were locally responsible for the clinical aspects of the study. MK,
JL and RG were in charge of the histopathological analysis. PS prepared the liver
specimens with the support of MK and MTa; MV and PSM were in charge of the
Senegalese cohort. VM was responsible for the French cohort, conceived the GPR
and revised the manuscript. MTh revised the design of the study and the
manuscript. YS was responsible for the statistical analysis.
Funding The study in The Gambia is part of the PROLIFICA programme funded by
the European commission: EC FP7, P34114. The study in Senegal was funded by
the ANRS (National Institute of Research on AIDS and Viral Hepatitis), France.
Competing interests None declared.
Ethics approval The Gambia Government/MRC (Medical Research Council) Joint
Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus
infection: new estimates of age-speciﬁc HBsAg seroprevalence and endemicity.
Vaccine 2012;30:2212–19.
2 Parkin DM, Sitas F, Chirenje M, et al. Part I: Cancer in Indigenous Africans—
burden, distribution, and trends. Lancet Oncol 2008;9:683–92.
3 Jemal A, Bray F, Forman D, et al. Cancer burden in Africa and opportunities for
prevention. Cancer 2012;118:4372–84.
4 Thursz M, Njie R, Lemoine M. Hepatitis: global eradication of hepatitis B-feasible or
fallacy? Nat Rev Gastroenterol Hepatol 2012;9:492–4.
5 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B
or C. Gastroenterology 2012;142:1293–302 e4.
6 Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver ﬁbrosis by
stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29:242–7.
7 Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison
to liver ﬁbrosis biomarkers in chronic viral hepatitis: a multicenter prospective study
(the FIBROSTIC study). J Hepatol 2010;53:1013–21.
8 Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of
liver stiffness measurement by transient elastography (Fibroscan) for liver ﬁbrosis in
chronic hepatitis B. J Viral Hepat 2009;16:36–44.
9 Kim do Y, Kim SU, Ahn SH, et al. Usefulness of FibroScan for detection of early
compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci 2009;54:1758–63.
10 Cardoso AC, Carvalho-Filho RJ, Stern C, et al. Direct comparison of diagnostic
performance of transient elastography in patients with chronic hepatitis B and
chronic hepatitis C. Liver Int 2012;32:612–21.
11 Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict
both signiﬁcant ﬁbrosis and cirrhosis in patients with chronic hepatitis C.
Hepatology 2003;38:518–26.
12 Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index
to predict signiﬁcant ﬁbrosis in patients with HIV/HCV coinfection. Hepatology
2006;43:1317–25.
13 WHO. World Health Organization. Guidelines for the Prevention, Care and
Treatment of Persons with chronic Hepatitis B infection. 2015. http://whoint/hiv/pub/
hepatitis/hepatitis-b-guidelines/en/ (accessed 17 Mar 2015).
14 Bonnard P, Sombie R, Lescure FX, et al. Comparison of elastography,
serum marker scores, and histology for the assessment of liver ﬁbrosis in
hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg
2010;82:454–8.
15 Mbaye PS, Sarr A, Sire JM, et al. Liver stiffness measurement and biochemical
markers in Senegalese chronic hepatitis B patients with normal ALT and high viral
load. PLoS ONE 2011;6:e22291.
16 http://www.proliﬁca.eu NCT02129829 clinicaltrialsorg. (15 Mar 2015).
17 Mallet V, Dhalluin-Venier V, Roussin C, et al. The accuracy of the FIB-4 index for
the diagnosis of mild ﬁbrosis in chronic hepatitis B. Aliment Pharmacol Ther
2009;29:409–15.
18 Njai HF, Shimakawa Y, Sanneh B, et al. Validation of rapid point-of-care
(POC) tests for the detection of hepatitis B surface antigen (HBsAg) in ﬁeld
and laboratory settings in The Gambia, West Africa. J Clin Microbiol
2015;53:1156–63.
19 Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker
of liver ﬁbrosis inﬂuenced by major changes of transaminases. J Viral Hepat
2007;14:360–9.
20 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis
C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.
21 Lemoine M, Shimakawa Y, Njie R, et al. Food intake increases liver stiffness
measurements and hampers reliable values in patients with chronic hepatitis B and
healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther
2014;39:188–96.
22 Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new
noninvasive method for assessment of hepatic ﬁbrosis. Ultrasound Med Biol
2003;29:1705–13.
23 Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria
for liver stiffness evaluation by transient elastography. Hepatology
2013;57:1182–91.
24 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting
of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med
2003;138:40–4.
25 Castera L, Foucher J, Bertet J, et al. FibroScan and FibroTest to assess liver ﬁbrosis
in HCV with normal aminotransferases. Hepatology 2006;43:373–4; author reply
5–6.
26 Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver ﬁbrosis
by measurement of stiffness in patients with chronic hepatitis C. Hepatology
2005;41:48–54.
27 Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient
elastography, Fibrotest, APRI, and liver biopsy for the assessment of ﬁbrosis in
chronic hepatitis C. Gastroenterology 2005;128:343–50.
28 Castera L, Bernard PH, Le Bail B, et al. Transient elastography and biomarkers for
liver ﬁbrosis assessment and follow-up of inactive hepatitis B carriers. Aliment
Pharmacol Ther 2011;33:455–65.
29 Suthar AB, Rutherford GW, Horvath T, et al. Improving antiretroviral therapy
scale-up and effectiveness through service integration and decentralization. Aids
2014;28(Suppl 2):S175–85.
30 Shin WG, Park SH, Jang MK, et al. Aspartate aminotransferase to platelet ratio
index (APRI) can predict liver ﬁbrosis in chronic hepatitis B. Dig Liver Dis
2008;40:267–74.
31 Lemoine M, Njai HF, Shimakawa Y, et al. Rural and urban community-based
screening for HBs antigen in the Gambia: assessment of chronic hepatitis B and
proportion of eligible patients for antiviral therapy. J Hepatol 2013;58.
32 Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with
biochemical markers in patients with chronic hepatitis B. J Hepatol
2003;39:222–30.
33 Vardar R, Vardar E, Demiri S, et al. Is there any non-invasive marker replace the
needle liver biopsy predictive for liver ﬁbrosis, in patients with chronic hepatitis?
Hepatogastroenterology 2009;56:1459–65.
34 Eminler AT, Irak K, Ayyildiz T, et al. The relation between liver histopathology and
GGT levels in viral hepatitis: more important in hepatitis B. Turk J Gastroenterol
2014;25:411–15.
35 Choi BC. Sensitivity and speciﬁcity of a single diagnostic test in the presence of
work-up bias. J Clin Epidemiol 1992;45:581–6.
36 Bedossa P, Dargere D, Paradis V. Sampling variability of liver ﬁbrosis in chronic
hepatitis C. Hepatology 2003;38:1449–57.
1376 Lemoine M, et al. Gut 2016;65:1369–1376. doi:10.1136/gutjnl-2015-309260
Hepatology
